AKL, a company developing an investigational osteoarthritis (OA) medicine, announces the appointment of Dr Annalisa Jenkins and Lord Michael Grade as advisors.
Dr Jenkins is former Head of Global Research & Development and Executive Vice President Global Development & Medical at Merck Serono. Lord Grade is former Chairman of the BBC.
Current Chief Operating Officer (COO) of AKL David Miles has been promoted to Chief Executive Officer (CEO), replacing previous CEO David Sharples who becomes Chairman. Clinical Scientist Alan Reynolds, who has extensive experience in inflammation and autoimmune disease treatments, has taken the role of Chief Science Officer (CSO).
The new appointments and change of roles come as AKL enters its next phase of bringing its investigational medicine APPA to market. Currently in Phase I clinical trials at Liverpool University, APPA is an NFkB and Nrf2 modulator which harnesses the power of two secondary metabolites of plant origin in a fully synthetic oral therapy and is a potential novel treatment for OA.
For more information please click here